Development of an adherence-enhancing intervention in topical treatment termed the topical treatment optimization program (TTOP)

Kristian Reich, Ulrich Mrowietz, Eleni Karakasili, Ina Zschocke, Kristian Reich, Ulrich Mrowietz, Eleni Karakasili, Ina Zschocke

Abstract

Psoriasis is a common, disabling, chronic, relapsing, inflammatory disorder of the skin with a worldwide prevalence of 2-3 % in which adherence to treatment is often poor. The majority of individuals have limited disease that is being treated with topical medication according to existing guidelines. Adherence rates are lower for topical compared with systemic treatment. Low medication adherence is a major problem for patients with chronic disorders as it results in suboptimal treatment outcomes, increased risk for development of concomitant diseases, inefficient use of health resources and considerable losses to society. However, to date no adherence-enhancing intervention has been developed for psoriasis patients under topical treatment. In this article, we report the development of the topical treatment optimization program (TTOP). The TTOP intervention aims to improve the information given to the patients and to result in an engaged patient-physician relationship. Application of the TTOP intervention in daily clinical practice may lead to a significant increase of adherence and the successful management of psoriasis and other chronic skin disorders.

References

    1. Anderson B. Collaborative care and motivational interviewing: improving depression outcomes through patient empowerment interventions. Am J Manag Care. 2007;13:S103–S106.
    1. Augustin M, Chapnik K, Gupta S, Buesch K, Radke M. Psoriasis causes high costs, reduces productivity at work and quality of life. Aktuelle Dermatol. 2011;37:353–359. doi: 10.1055/s-0030-1256636.
    1. Augustin M, Holland B, Dartsch D, Langenbruch A, Radtke MA. Adherence in the treatment of psoriasis: a systematic review. Dermatology. 2011;222:363–374. doi: 10.1159/000329026.
    1. Balkrishnan R, Carroll CL, Camacho FT, Feldman SR. Electronic monitoring of medication adherence in skin disease: results of a pilot study. J Am Acad Dermatol. 2003;49:651–654. doi: 10.1067/S0190-9622(03)00912-5.
    1. Barber N, Parsons J, Clifford S, Darracott R, Horne R. Patients’ problems with new medication for chronic conditions. Qual Saf Health Care. 2004;13:172–175. doi: 10.1136/qshc.2003.005926.
    1. Bewley A, Page B. Maximizing patient adherence for optimal outcomes in psoriasis. J Eur Acad Dermatol Venereol. 2011;25:9–14. doi: 10.1111/j.1468-3083.2011.04060.x.
    1. Brawley LR, Culos-Reed SN. Studying adherence to therapeutic regimens: overview, theories, recommendations. Control Clin Trials. 2000;21:156S–163S. doi: 10.1016/S0197-2456(00)00073-8.
    1. Brown KK, Wingfield ER, Kimball AB. Determining the relative importance of patient motivations for nonadherence to topical corticosteroid therapy in psoriasis. J Am Acad Dermatol. 2006;55:607–613. doi: 10.1016/j.jaad.2005.12.021.
    1. Brown MT, Bussell JK (2011) Medication adherence: WHO cares? Mayo Clin Proc 86(4):304–314
    1. Carroll CL, Feldman SR, Camacho FT, Balkrishnan R. Better medication adherence results in greater improvement in severity of psoriasis. Br J Dermatol. 2004;151:895–897. doi: 10.1111/j.1365-2133.2004.06174.x.
    1. Carroll CL, Feldman SR, Camacho FT, Manuel JC, Balkrishnan R. Adherence to topical therapy decreases during the course of an 8-week psoriasis clinical trial: commonly used methods of measuring adherence to topical therapy overestimate actual use. J Am Acad Dermatol. 2004;51:212–216. doi: 10.1016/j.jaad.2004.01.052.
    1. Culos-Reed SN, Rejeski WJ, McAuley E, Ockene JK, Roter DL. Predictors of adherence to behavior change interventions in the elderly. Control Clin Trials. 2000;21:200S–205S. doi: 10.1016/S0197-2456(00)00079-9.
    1. de Korte J, Van Onselen J, Kownacki S, Sprangers MA, Bos JD. Quality of care in patients with psoriasis: an initial clinical study of an international disease management programme. J Eur Acad Dermatol Venereol. 2005;19:35–41. doi: 10.1111/j.1468-3083.2004.01107.x.
    1. Dimatteo MR, Giordani PJ, Lepper HS, Croghan TW. Patient adherence and medical treatment outcomes: a meta-analysis. Med Care. 2002;40:794–811. doi: 10.1097/00005650-200209000-00009.
    1. Elliott R. Non-adherence to medicines: not solved but solvable. J Health Serv Res Policy. 2009;14:58–61. doi: 10.1258/jhsrp.2008.008088.
    1. Ellis S, Shumaker S, Sieber W, Rand C. Adherence to pharmacological interventions. Current trends and future directions. The Pharmacological Intervention Working Group. Control Clin Trials. 2000;21:218S–225S. doi: 10.1016/S0197-2456(00)00082-9.
    1. Evers AW, Kleinpenning MM, Smits T, Boezeman J, van de Kerkhof PC, Kraaimaat FW, Gerritsen MJ. Treatment nonadherence and long-term effects of narrowband UV-B therapy in patients with psoriasis. Arch Dermatol. 2010;146:198–199. doi: 10.1001/archdermatol.2009.382.
    1. Falvo D, Tippy P. Communicating information to patients. Patient satisfaction and adherence as associated with resident skill. J Fam Pract. 1988;26:643–647.
    1. Farrer L, Christensen H, Griffiths KM, Mackinnon A. Internet-based CBT for depression with and without telephone tracking in a national helpline: randomised controlled trial. PLoS One. 2011;6:e28099. doi: 10.1371/journal.pone.0028099.
    1. Feldman S, Behnam SM, Behnam SE, Koo JY. Involving the patient: impact of inflammatory skin disease and patient-focused care. J Am Acad Dermatol. 2005;53:S78–S85. doi: 10.1016/j.jaad.2005.04.033.
    1. Feldman SR. Approaching psoriasis differently: patient–physician relationships, patient education and choosing the right topical vehicle. J Drugs Dermatol. 2010;9:908–911.
    1. Feldman SR, Camacho FT, Krejci-Manwaring J, Carroll CL, Balkrishnan R. Adherence to topical therapy increases around the time of office visits. J Am Acad Dermatol. 2007;57:81–83. doi: 10.1016/j.jaad.2007.04.005.
    1. Feldman SR, Horn EJ, Balkrishnan R, Basra MK, Finlay AY, McCoy D, Menter A, van de Kerkhof PC, International Psoriasis Council Psoriasis: improving adherence to topical therapy. J Am Acad Dermatol. 2008;59:1009–1016. doi: 10.1016/j.jaad.2008.08.028.
    1. Finlay AY, Coles EC. The effect of severe psoriasis on the quality of life of 369 patients. Br J Dermatol. 1995;132:236–244. doi: 10.1111/j.1365-2133.1995.tb05019.x.
    1. Fouere S, Adjadj L, Pawin H. How patients experience psoriasis: results from a European survey. J Eur Acad Dermatol Venereol. 2005;19(Suppl 3):2–6. doi: 10.1111/j.1468-3083.2005.01329.x.
    1. Fuertes JN, Mislowack A, Bennett J, Paul L, Gilbert TC, Fontan G, Boylan LS. The physician-patient working alliance. Patient Educ Couns. 2007;66:29–36. doi: 10.1016/j.pec.2006.09.013.
    1. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. J Am Med Assoc. 2006;296:1735–1741. doi: 10.1001/jama.296.14.1735.
    1. Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X (2008) Interventions for enhancing medication adherence. Cochrane Database Syst Rev (2):CD000011. doi: 10.1002/14651858.CD000011.pub3
    1. Hays RD, Kravitz RL, Mazel RM, Sherbourne CD, Dimatteo MR, Rogers WH, Greenfield S. The impact of patient adherence on health outcomes for patients with chronic disease in the Medical Outcomes Study. J Behav Med. 1994;17:347–360. doi: 10.1007/BF01858007.
    1. Hodari KT, Nanton JR, Carroll CL, Feldman SR, Balkrishnan R. Adherence in dermatology: a review of the last 20 years. J Dermatol Treat. 2006;17:136–142. doi: 10.1080/09546630600688515.
    1. Hong J, Koo B, Koo J. The psychosocial and occupational impact of chronic skin disease. Dermatol Ther. 2008;21:54–59. doi: 10.1111/j.1529-8019.2008.00170.x.
    1. Horning KK, Hoehns JD, Doucette WR. Adherence to clinical practice guidelines for 7 chronic conditions in long-term-care patients who received pharmacist disease management services versus traditional drug regimen review. J Manag Care Pharm. 2007;13:28–36.
    1. Hovstadius B, Petersson G. Non-adherence to drug therapy and drug acquisition costs in a national population—a patient-based register study. BMC Health Serv Res. 2011;11:326. doi: 10.1186/1472-6963-11-326.
    1. Huffman MH. HEALTH COACHING: a fresh, new approach to improve quality outcomes and compliance for patients with chronic conditions. Home Healthc Nurse. 2009;27:490–496. doi: 10.1097/01.NHH.0000360924.64474.04.
    1. Kaye JA, Li L, Jick SS. Incidence of risk factors for myocardial infarction and other vascular diseases in patients with psoriasis. Br J Dermatol. 2008;159:895–902. doi: 10.1111/j.1365-2133.2008.08707.x.
    1. Kennedy A, Nelson E, Reeves D, Richardson G, Roberts C, Robinson A, Rogers A, Sculpher M, Thompson D. A randomised controlled trial to assess the impact of a package comprising a patient-orientated, evidence-based self-help guidebook and patient-centred consultations on disease management and satisfaction in inflammatory bowel disease. Health Technol Assess. 2003;7:3.
    1. Koo J. Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Dermatol Clin. 1996;14:485–496. doi: 10.1016/S0733-8635(05)70376-4.
    1. Kravitz RL, Hays RD, Sherbourne CD, Dimatteo MR, Rogers WH, Ordway L, Greenfield S. Recall of recommendations and adherence to advice among patients with chronic medical conditions. Arch Intern Med. 1993;153:1869–1878. doi: 10.1001/archinte.1993.00410160029002.
    1. Kripalani S, Robertson R, Love-Ghaffari MH, Henderson LE, Praska J, Strawder A, Katz MG, Jacobson TA. Development of an illustrated medication schedule as a low-literacy patient education tool. Patient Educ Couns. 2007;66:368–377. doi: 10.1016/j.pec.2007.01.020.
    1. Kripalani S, Yao X, Haynes RB. Interventions to enhance medication adherence in chronic medical conditions: a systematic review. Arch Intern Med. 2007;167:540–550. doi: 10.1001/archinte.167.6.540.
    1. Kucukarslan SN, Thomas S, Bazzi A, Virant-Young D. Using self-regulation theory to examine patient goals, barriers, and facilitators for taking medication. Patient. 2009;2:211–220. doi: 10.2165/11313830-000000000-00000.
    1. Langley RG, Ellis CN. Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician’s Global Assessment. J Am Acad Dermatol. 2004;51:563–569. doi: 10.1016/j.jaad.2004.04.012.
    1. Langley RG, Krueger GG, Griffiths CE. Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis. 2005;64(Suppl 2):ii18–ii23.
    1. Lawrence DB, Allison W, Chen JC, Demand M. Improving medication adherence with a targeted, technology-driven disease management intervention. Dis Manag. 2008;11:141–144. doi: 10.1089/dis.2007.0013.
    1. Lebwohl M, Ali S. Treatment of psoriasis. Part 1. Topical therapy and phototherapy. J Am Acad Dermatol. 2001;45:487–498. doi: 10.1067/mjd.2001.117046.
    1. Lee IA, Maibach HI. Pharmionics in dermatology: a review of topical medication adherence. Am J Clin Dermatol. 2006;7:231–236. doi: 10.2165/00128071-200607040-00004.
    1. Leiva A, Fajo M, Escriche L, Audera FJ, Lopez S, Martin MC, Gonzalez R, Tamborero G, Garcia EM, Duro R, Orueta R, Serra F, D’agosto PP, Miralles J, Lorente P, Llobera J, Iglesias AA, Fernandez R, Colom MM, Buades AM, Moreno L, Vidal C. Efficacy of a brief multifactorial adherence-based intervention on reducing the blood pressure of patients with poor adherence: protocol for a randomized clinical trial. BMC Cardiovasc Disord. 2010;10:44. doi: 10.1186/1471-2261-10-44.
    1. Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature. 2007;445:866–873. doi: 10.1038/nature05663.
    1. Lundberg L, Johannesson M, Silverdahl M, Hermansson C, Lindberg M. Quality of life, health-state utilities and willingness to pay in patients with psoriasis and atopic eczema. Br J Dermatol. 1999;141:1067–1075. doi: 10.1046/j.1365-2133.1999.03207.x.
    1. Martin LR, Williams SL, Haskard KB, Dimatteo MR. The challenge of patient adherence. Ther Clin Risk Manag. 2005;1:189–199.
    1. Matsui D. Strategies to measure and improve patient adherence in clinical trials. Pharm Med. 2009;23:289–297. doi: 10.1007/BF03256784.
    1. Menter A, Griffiths CE. Current and future management of psoriasis. Lancet. 2007;370:272–284. doi: 10.1016/S0140-6736(07)61129-5.
    1. Mosen DM, Schmittdiel J, Hibbard J, Sobel D, Remmers C, Bellows J. Is patient activation associated with outcomes of care for adults with chronic conditions? J Ambul Care Manage. 2007;30:21–29. doi: 10.1097/00004479-200701000-00005.
    1. Mrowietz U, Kragballe K, Reich K, Spuls P, Griffiths CE, Nast A, Franke J, Antoniou C, Arenberger P, Balieva F, Bylaite M, Correia O, Dauden E, Gisondi P, Iversen L, Kemeny L, Lahfa M, Nijsten T, Rantanen T, Reich A, Rosenbach T, Segaert S, Smith C, Talme T, Volc-Platzer B, Yawalkar N. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res. 2011;303:1–10. doi: 10.1007/s00403-010-1080-1.
    1. Mullen PD, Green LW, Persinger GS. Clinical trials of patient education for chronic conditions: a comparative meta-analysis of intervention types. Prev Med. 1985;14:753–781. doi: 10.1016/0091-7435(85)90070-2.
    1. Nast A, Boehncke W-H, Mrowietz U, Ockenfels HM, Philipp S, Reich K, Rosenbach T, Sammain A, Schlaeger M, Sebastian M, Sterry W, Streit V, Augustin M, Erdmann R, Klaus J, Koza J, Müller S, Orzechowski HD, Rosumeck S, Schmid-Ott G, Weberschock T, Rzany B. S3-Leitlinie zur Therapie der Psoriasis vulgaris Update 2011. J Dtsch Dermatol Ges. 2011;9:S1–S104.
    1. Nast A, Erdmann R, Pathirana D, Rzany B. Translating psoriasis treatment guidelines into clinical practice—the need for educational interventions and strategies for broad dissemination. J Eval Clin Pract. 2008;14:803–806. doi: 10.1111/j.1365-2753.2008.00971.x.
    1. Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB, Gelfand JM. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol. 2006;55:829–835. doi: 10.1016/j.jaad.2006.08.040.
    1. Nichol MB, Knight TK, Priest JL, Wu J, Cantrell CR. Nonadherence to clinical practice guidelines and medications for multiple chronic conditions in a California Medicaid population. J Am Pharm Assoc (2003) 2010;50:496–507. doi: 10.1331/JAPhA.2010.09123.
    1. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487–497. doi: 10.1056/NEJMra050100.
    1. Pagliarello C, Di PC, Paradisi A, Abeni D, Tabolli S. Measuring empowerment in patients with psoriasis: the Psoriasis Empowerment Enquiry in the Routine Practice (PEER) questionnaire. Eur J Dermatol. 2010;20:200–204.
    1. Renzi C, Abeni D, Picardi A, Agostini E, Melchi CF, Pasquini P, Puddu P, Braga M. Factors associated with patient satisfaction with care among dermatological outpatients. Br J Dermatol. 2001;145:617–623. doi: 10.1046/j.1365-2133.2001.04445.x.
    1. Renzi C, Tabolli S, Picardi A, Abeni D, Puddu P, Braga M. Effects of patient satisfaction with care on health-related quality of life: a prospective study. J Eur Acad Dermatol Venereol. 2005;19:712–718. doi: 10.1111/j.1468-3083.2005.01301.x.
    1. Richards HL, Fortune DG, Griffiths CE. Adherence to treatment in patients with psoriasis. J Eur Acad Dermatol Venereol. 2006;20:370–379. doi: 10.1111/j.1468-3083.2006.01565.x.
    1. Richards HL, Fortune DG, O’Sullivan TM, Main CJ, Griffiths CE. Patients with psoriasis and their compliance with medication. J Am Acad Dermatol. 1999;41:581–583.
    1. Riley KM, Glasgow RE, Eakin EG. Resources for health: a social-ecological intervention for supporting self-management of chronic conditions. J Health Psychol. 2001;6:693–705. doi: 10.1177/135910530100600607.
    1. Sabaté E (2003) Adherence to long-term therapies—evidence for action, WHO, WHO1-211 , Accessed 16 Jan 2014
    1. Sackett DL, Haynes RB, Gibson ES, Taylor DW, Roberts RS, Johnson AL. Patient compliance with antihypertensive regimens. Patient Couns Health Educ. 1978;1:18–21. doi: 10.1016/S0738-3991(78)80033-0.
    1. Sahm L, MacCurtain A, Hayden J, Roche C, Richards HL. Electronic reminders to improve medication adherence–are they acceptable to the patient? Pharm World Sci. 2009;31:627–629. doi: 10.1007/s11096-009-9327-7.
    1. Schoffski O, Augustin M, Prinz J, Rauner K, Schubert E, Sohn S, Reich K. Costs and quality of life in patients with moderate to severe plaque-type psoriasis in Germany: a multi-center study. J Dtsch Dermatol Ges. 2007;5:209–218. doi: 10.1111/j.1610-0387.2007.06240.x.
    1. Schulman BA, Swain MA. Active patient orientation. Patient Couns Health Educ. 1980;2:32–37. doi: 10.1016/S0738-3991(80)80027-9.
    1. Sohn S, Schoeffski O, Prinz J, Reich K, Schubert E, Waldorf K, Augustin M. Cost of moderate to severe plaque psoriasis in Germany: a multicenter cost-of-illness study. Dermatology. 2006;212:137–144. doi: 10.1159/000090654.
    1. Stein GL, Corvari L. The roles of safety and compliance in determining effectiveness of topical therapy for psoriasis. Cutis. 2007;79:32–38.
    1. Stilley CS, Bender CM, Dunbar-Jacob J, Sereika S, Ryan CM. The impact of cognitive function on medication management: three studies. Health Psychol. 2010;29:50–55. doi: 10.1037/a0016940.
    1. Storm A, Andersen SE, Benfeldt E, Serup J. One in 3 prescriptions are never redeemed: primary nonadherence in an outpatient clinic. J Am Acad Dermatol. 2008;59:27–33. doi: 10.1016/j.jaad.2008.03.045.
    1. Storm A, Benfeldt E, Andersen SE, Andersen J. Basic drug information given by physicians is deficient, and patients’ knowledge low. J Dermatol Treat. 2009;20:190–193. doi: 10.1080/09546630802570818.
    1. Storm A, Benfeldt E, Andersen SE, Serup J. A prospective study of patient adherence to topical treatments: 95 % of patients underdose. J Am Acad Dermatol. 2008;59:975–980. doi: 10.1016/j.jaad.2008.07.039.
    1. Uhlenhake EE, Kurkowski D, Feldman SR. Conversations on psoriasis—what patients want and what physicians can provide: a qualitative look at patient and physician expectations. J Dermatol Treat. 2010;21:6–12. doi: 10.3109/09546630903085328.
    1. van de Kerkhof PC, de Hoop D, de Korte J, Cobelens SA, Kuipers MV. Patient compliance and disease management in the treatment of psoriasis in the Netherlands. Dermatology. 2000;200:292–298. doi: 10.1159/000018390.
    1. Williams A, Manias E, Walker R. Interventions to improve medication adherence in people with multiple chronic conditions: a systematic review. J Adv Nurs. 2008;63:132–143. doi: 10.1111/j.1365-2648.2008.04656.x.
    1. Zaghloul SS, Goodfield MJ. Objective assessment of compliance with psoriasis treatment. Arch Dermatol. 2004;140:408–414. doi: 10.1001/archderm.140.4.408.
    1. Zschocke I, Mrowietz U, Lotzin A, Karakasili E, Reich K. Assessing adherence factors in patients under topical treatment: development of the Topical Therapy Adherence Questionnaire (TTAQ) Arch Dermatol Res. 2014;306:287–297. doi: 10.1007/s00403-014-1446-x.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe